- Incyte (INCY, Financial) to present new data from its early-stage oncology portfolio at AACR 2025.
- Highlights include advancements in treatments for myeloproliferative neoplasms and ovarian cancer.
- Key presentations involve promising results from novel therapeutics like INCB177054 and INCA33890.
Incyte Corporation (INCY) has announced its plans to unveil new early-stage oncology data at the American Association for Cancer Research (AACR) Annual Meeting, scheduled for April 25-30, 2025, in Chicago, Illinois. The presentations will include findings from its innovative oncology pipeline, focusing on advancements for patients with myeloproliferative neoplasms, ovarian cancer, and other solid tumors.
One of the highlights includes the presentation of INCB177054, a novel, potent, orally bioavailable DGKα/ζ dual inhibitor. This compound has shown to enhance T-Cell function and demonstrates potent antitumor activity. The mini symposium will feature this data on April 28.
During the poster presentations on April 29, Incyte will discuss the efficacy of INCA33890, a bispecific antibody targeting PD-1 and TGFβR2. This therapeutic has shown enhanced immune responses in models of ovarian cancer, and has been assessed by single-cell RNA sequencing in a human PD-1xTGFβR2 knock-in mouse model, indicating a potential for superior CD8+ T-Cell effector function compared to pembrolizumab.
April 30 will see presentations on INCB057643, a BET protein inhibitor that has shown promise in improving bone marrow function and shifting megakaryopoiesis to erythropoiesis in patients with myeloproliferative neoplasms. Additionally, this compound plays a novel role in myeloid cell regulation and remodeling of the immunosuppressive tumor environment in myelofibrosis.
Incyte's commitment to transforming the treatment landscape for cancer patients continues as it advances its robust pipeline, highlighted by these insights shared at AACR 2025. For further details, interested parties can visit Incyte's official website.
